Evidence map›Paper›PMID 31573641›Full record

ReviewJAMA2019

Chronic Kidney Disease Diagnosis and Management: A Review.

Teresa K Chen, Daphne H Knicely, Morgan E Grams

Registry-linked trialAbstract readReview
In one paragraph

Review in JAMA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07049718 (Effect of Whole-body Vibration Training on Bone Mineral Density and Physical Performance in Patient With Renal Dialysis), which is not on this map. Cited by 930 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
930citing papers in PubMed, 5 pooled it
71.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07049718 nacompletednot on this mapstarted 2025, after this paper: background citation

Effect of Whole-body Vibration Training on Bone Mineral Density and Physical Performance in Patient With Renal Dialysis

TypeinterventionalSponsorCairo UniversityRan2025 to 2025Enrolled60ConditionsRenal DialysisArmswhole body vibration
3 · Its place in the literature

Who cites it

930 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,669 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

870 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Teresa K ChenDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Daphne H KnicelyDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Morgan E GramsDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S. · 2008 to 2022
$16.8M
Chronic Kidney Disease Prognosis Consortium (CKD-PC)R01DK100446 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JOSEF CORESH, Morgan Erika Grams · 2014 to 2026
$10.7M
Multi-Omics and Chronic Kidney Disease: Correlation with HistologyR01DK108803 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Morgan Erika Grams, EUGENE P. RHEE · 2016 to 2026
$6.4M
Medication Use and Adverse Events in CKDR01DK115534 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Alexander R Chang, Morgan Erika Grams · 2018 to 2026
$5.7M
Biomarkers of Immune Activation in African Americans with CKDK08DK117068 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, TERESA · 2019 to 2023
$961k
NIDDK NIH HHS K08 DK117068NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK100446NIDDK NIH HHS R01 DK108803NIDDK NIH HHS R01 DK115534
6 · The paper itself

Abstract

Importance: Chronic kidney disease (CKD) is the 16th leading cause of years of life lost worldwide. Appropriate screening, diagnosis, and management by primary care clinicians are necessary to prevent adverse CKD-associated outcomes, including cardiovascular disease, end-stage kidney disease, and death. Observations: Defined as a persistent abnormality in kidney structure or function (eg, glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria ≥30 mg per 24 hours) for more than 3 months, CKD affects 8% to 16% of the population worldwide. In developed countries, CKD is most commonly attributed to diabetes and hypertension. However, less than 5% of patients with early CKD report awareness of their disease. Among individuals diagnosed as having CKD, staging and new risk assessment tools that incorporate GFR and albuminuria can help guide treatment, monitoring, and referral strategies. Optimal management of CKD includes cardiovascular risk reduction (eg, statins and blood pressure management), treatment of albuminuria (eg, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers), avoidance of potential nephrotoxins (eg, nonsteroidal anti-inflammatory drugs), and adjustments to drug dosing (eg, many antibiotics and oral hypoglycemic agents). Patients also require monitoring for complications of CKD, such as hyperkalemia, metabolic acidosis, hyperphosphatemia, vitamin D deficiency, secondary hyperparathyroidism, and anemia. Those at high risk of CKD progression (eg, estimated GFR <30 mL/min/1.73 m2, albuminuria ≥300 mg per 24 hours, or rapid decline in estimated GFR) should be promptly referred to a nephrologist. Conclusions and Relevance: Diagnosis, staging, and appropriate referral of CKD by primary care clinicians are important in reducing the burden of CKD worldwide.

Indexed as

Renal Insufficiency, ChronicDiabetes ComplicationsDisease ProgressionGlomerular Filtration RateHumansHypertensionPrognosisReferral and ConsultationRisk Assessment

Identifiers

PMID31573641
PMCPMC7015670
OpenAlexW2977682063

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.